Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer

A 44-year-old woman with advanced metastatic colon cancer received chemotherapies comprising oxaliplatin and capecitabine (XELOX), irinotecan hydrochloride, leucovorin calcium and fluorouracil irinotecan (FOLFIRI)/panitumumab and mFOLFOX6/bevacizumab. Fifteen months later, she presented with the acu...

Descripción completa

Detalles Bibliográficos
Autores principales: Katada, Eiichi, Mitsui, Akira, Sasaki, Shigeru, Uematsu, Norihiko, Anan, Chise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148172/
https://www.ncbi.nlm.nih.gov/pubmed/29526944
http://dx.doi.org/10.2169/internalmedicine.0284-17
_version_ 1783356715103682560
author Katada, Eiichi
Mitsui, Akira
Sasaki, Shigeru
Uematsu, Norihiko
Anan, Chise
author_facet Katada, Eiichi
Mitsui, Akira
Sasaki, Shigeru
Uematsu, Norihiko
Anan, Chise
author_sort Katada, Eiichi
collection PubMed
description A 44-year-old woman with advanced metastatic colon cancer received chemotherapies comprising oxaliplatin and capecitabine (XELOX), irinotecan hydrochloride, leucovorin calcium and fluorouracil irinotecan (FOLFIRI)/panitumumab and mFOLFOX6/bevacizumab. Fifteen months later, she presented with the acute onset of a headache, drowsiness and seizure with a fever and hypertension. Brain magnetic resonance imaging (MRI) indicated bilateral regions of signal hyperintensity in the white matter with spasms of bilateral cerebral arteries apparent on magnetic resonance angiography. Posterior reversible encephalopathy syndrome (PRES) was diagnosed, and treatments resulted in improvement of the MRI findings, but the patient experienced cerebral infarction and ultimately died of deterioration of cancer on day 26 after the onset of PRES.
format Online
Article
Text
id pubmed-6148172
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-61481722018-09-25 Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer Katada, Eiichi Mitsui, Akira Sasaki, Shigeru Uematsu, Norihiko Anan, Chise Intern Med Case Report A 44-year-old woman with advanced metastatic colon cancer received chemotherapies comprising oxaliplatin and capecitabine (XELOX), irinotecan hydrochloride, leucovorin calcium and fluorouracil irinotecan (FOLFIRI)/panitumumab and mFOLFOX6/bevacizumab. Fifteen months later, she presented with the acute onset of a headache, drowsiness and seizure with a fever and hypertension. Brain magnetic resonance imaging (MRI) indicated bilateral regions of signal hyperintensity in the white matter with spasms of bilateral cerebral arteries apparent on magnetic resonance angiography. Posterior reversible encephalopathy syndrome (PRES) was diagnosed, and treatments resulted in improvement of the MRI findings, but the patient experienced cerebral infarction and ultimately died of deterioration of cancer on day 26 after the onset of PRES. The Japanese Society of Internal Medicine 2018-03-09 2018-08-15 /pmc/articles/PMC6148172/ /pubmed/29526944 http://dx.doi.org/10.2169/internalmedicine.0284-17 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Katada, Eiichi
Mitsui, Akira
Sasaki, Shigeru
Uematsu, Norihiko
Anan, Chise
Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer
title Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer
title_full Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer
title_fullStr Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer
title_full_unstemmed Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer
title_short Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer
title_sort posterior reversible encephalopathy syndrome after a variety of combined chemotherapies containing bevacizumab for metastatic colon cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148172/
https://www.ncbi.nlm.nih.gov/pubmed/29526944
http://dx.doi.org/10.2169/internalmedicine.0284-17
work_keys_str_mv AT katadaeiichi posteriorreversibleencephalopathysyndromeafteravarietyofcombinedchemotherapiescontainingbevacizumabformetastaticcoloncancer
AT mitsuiakira posteriorreversibleencephalopathysyndromeafteravarietyofcombinedchemotherapiescontainingbevacizumabformetastaticcoloncancer
AT sasakishigeru posteriorreversibleencephalopathysyndromeafteravarietyofcombinedchemotherapiescontainingbevacizumabformetastaticcoloncancer
AT uematsunorihiko posteriorreversibleencephalopathysyndromeafteravarietyofcombinedchemotherapiescontainingbevacizumabformetastaticcoloncancer
AT ananchise posteriorreversibleencephalopathysyndromeafteravarietyofcombinedchemotherapiescontainingbevacizumabformetastaticcoloncancer

Ejemplares similares